Clinical pharmacology of rasagiline: A novel, second-generation propargylamine for the treatment of Parkinson disease

Journal of Clinical Pharmacology

Volumn 45, Issue 8, 2005, Pages 878-894

  Chen, Jack J ^a,b   Swope, David M ^a  

^a LOMA LINDA UNIVERSITY   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Monoamine oxidase; Neuroprotection; Parkinson disease; Propargylamines; Rasagiline

Indexed keywords

AMINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMINOINDAN; AMITRIPTYLINE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; CIMETIDINE; CIPROFLOXACIN; CYTOCHROME P450 1A2; CYTOCHROME P450 INHIBITOR; DECARBOXYLASE INHIBITOR; DRUG METABOLITE; ENTACAPONE; ENZYME INDUCING AGENT; FLUVOXAMINE; INDAN DERIVATIVE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; OMEPRAZOLE; PETHIDINE; PROPARGYLAMINE; RASAGILINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TV 1022; TYRAMINE; UNCLASSIFIED DRUG;

ANOREXIA; ANTIAPOPTOSIS ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BACKACHE; BALANCE DISORDER; BODY WEIGHT DISORDER; BRAIN PROTECTION; CARDIOVASCULAR DISEASE; CELL PROTECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DYSKINESIA; ENZYME INHIBITION; FOOD DRUG INTERACTION; HALLUCINATION; HEADACHE; HUMAN; INFECTION; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; MONOTHERAPY; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PAIN; PARKINSON DISEASE; PERIPHERAL EDEMA; REVIEW; SEROTONIN SYNDROME; SLEEP DISORDER; SOMNOLENCE; TIME TO REACH MAXIMUM PLASMA CONCENTRATION; VOMITING; WEIGHT REDUCTION;

ANIMALS; CLINICAL TRIALS; DRUG INTERACTIONS; HUMANS; INDANS; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SELEGILINE;

EID: 23044514579     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005277935     Document Type: Review

References (101)

1. Abeles RH, Tashjian AH Jr. Comparison of the inhibitory effects of propargylamine and pargyline on brain and liver monoamine oxidase activity. Biochem Pharmacol. 1975;24:307-308.
2. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline: an update. Clin Pharmacokinet. 1997;33:91-102.
3. Shin HS. Metabolism of selegiline in humans: identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos. 1997;25:657-662.
4. Yasar S, Goldberg JP, Goldberg SR. Are metabolites of 1-deprenyl (selegiline) useful or harmful? Indications from preclinical research. J Neural Transm Suppl. 1996;48:61-73.
5. Abu-Raya S, Tabakman R, Blaugrund E, Trembovler V, Lazarovici P. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol. 2002;434:109-116.
6. Bar-Am O, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett. 2004;355:169-172.
7. Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;63:228-234.
8. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937-1943.
9. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561-566.
10. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947-954.
11. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO Study. Arch Neurol. 2005;62:241-248.
12. Youdim MB, Bar Am O, Yogev-Falach M, et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005;79:172-179.
13. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004;363:1783-1793.
14. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci. In press.
15. Jenner P, Olanow CW. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 1996;47(suppl 3):S161-S170.
16. Riederer P, Youdim MBH, Rausch WD, Birkmayer W, Jellinger K, Seemann D. On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm. 1978;43:217-226.
17. Youdim MBH, Finberg JPM. Monoamine oxidase. In: Lajtha A, ed. Handbook of Neurochemistry. Vol 4: Enzymes in the Nervous System. New York: Plenum; 1983;293-313.
18. Saura Marti J, Kettler R, Da Prada M, Richards JG. Molecular neuroanatomy of MAO-A and MAO-B. J Neural Transm Suppl. 1990;32:49-53.
19. Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun. 1984;120:574-578.
20. Ghislandi V, Vercesi D. Optical resolution and configuration of 1-aminobenzocyclobutene and 1-aminoindane. Boll Chim Farm. 1976;115:489-500.
21. Binda C, Hubalek F, Li M, et al. Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J Med Chem. 2004;47:1767-1774.
22. Kalir A, Sabbagh A, Youdim MB. Selective acetylenic "suicide" and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol. 1981;73:55-64.
23. Maruyama W, Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech Ageing Dev. 1999;111:189-200.
24. Finberg JPM, Tenne M, Youdim MBH. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol. 1981;73:65-74.
25. Finberg JP, Lamensdorf I, Commissiong JW, Youdim MB. Pharmacology and neuroprotective properties of rasagiline. J Neural Trans. 1996;48(suppl):95-101.
26. Finberg JPM, Youdim MBH. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, type A and type B in the cat. Br J Pharmacol. 1985;85:541-546.
27. Sterling J, Veinberg A, Lerner D, et al. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transm Suppl. 1998;52:301-305.
28. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan] , a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol. 2001;132:500-506.
29. Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy. 2004;24:1295-1305.
30. Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000;23:324-330.
31. Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdim MB. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol. 1999;80:495-499.
32. Lamensdorf I, Youdim MB, Finberg JP. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem. 1996;67:1532-1539.
33. Finberg JP, Wang J, Bankiewicz K, Harvey-White J, Kopin IJ, Goldstein DS. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. J Neural Transm. 1998;52(suppl):279-285.
34. 11C]deprenyl and positron emission tomography (PET) [abstract]. Mov Disord. 2005;20(suppl 10):S89.
35. Hubalek F, Binda C, Li M, et al. Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. J Med Chem. 2004;47:1760-1766.
36. Green AR, Mitchell BD, Tordoff AF, Youdim MB. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol. 1977;60:343-349.
37. Youdim MB. Platelet monoamine oxidase B: use and misuse. Experientia. 1988;44:137-141.
38. Gotz ME, Breithaupt W, Sautter J, et al. Chronic TVP-1012 (rasagiline) dose-activity response of monoamine oxidases A and B in the brain of the common marmoset. J Neural Transm. 1998;52(suppl):271-278.
39. Stern MB, Marek KL, Friedman J, et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord. 2004;19:916-923.
40. Kamada T, Chow T, Hiroi T, et al. Metabolism of selegiline hydrochloride, a selective monoamine B-type inhibitor, in human liver microsomes. Drug Metab Pharmacokinet. 2002;17:199-206.
41. Salonen JS, Nyman L, Boobis AR, et al. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos. 2003;31:1093-1102.
42. Glezer S, Finberg JP. Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens. Eur J Pharmacol. 2003;472:173-177.
43. Cody JT. Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. J Occup Environ Med. 2002;44:435-450.
44. Finberg JPM, Tenne M, Youdim MBH. Selective irreversible propargyl derivative inhibitors of monoamine oxidase (MAO) without the cheese effect. In: Youdim MBH, Paykel ES, eds. Monoamine Oxidase Inhibitors: The State of the Art. London, UK: Wiley & Sons; 1981:31-44.
45. Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after deprenyl (selegiline) withdrawal. Synapse. 1994;18:86-93.
46. Fahn S, Elton RL, UPDRS Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, et al., eds. Recent Developments in Parkinson's Disease. Vol 2. Florham Park, NJ: Macmillan Health Care Information; 1987:153-164.
47. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351:2498-2508.
48. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J. Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson's disease [abstract]. Mov Disord. 2005;20(suppl 10):S75.
49. Chen JJ, Berchou RC. Rasagiline, a selective, second-generation, irreversible inhibitor of monoamine oxidase type B, is effective in patients older and younger than 65 years of age with early-to-advanced Parkinson's disease (PD) [abstract]. Pharmacotherapy. 2004;24:1448.
50. Montastruc JL, Chaumerliac C, Desboeuf K, et al. Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. Clin Neuropharmacol. 2000;23:271-275.
51. Gill JR Jr, Masson DT, Bartter FC. Effects of hydroxyamphetamine on the function of the sympathetic nervous system in normotensive subjects. J Pharmacol Exp Ther. 1967;155:288-295.
52. Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective and behavioural effects of amphetamine, metamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther. 1971;12:245-260.
53. Abassi ZA, Binah O, Youdim MB. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol. 2004;143:371-378.
54. Elmer L, on behalf of the Parkinson Study Group. Rasagiline is effective and well tolerated in the treatment of Parkinson's disease (PD) patients with levodopa-related motor fluctuations receiving other adjunctive therapy [abstract]. Mov Disord. 2005;20(suppl 10):S138.
55. Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I. Safety of rasagiline in elderly Parkinson's disease (PD) patients [abstract]. Mov Disord. 2005;20(suppl 10):S81.
56. Moses D, Gross A, Finberg JP. Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig. Neuropharmacology. 2004;47:72-80.
57. Schulz R, Antonin KH, Hoffmann E, et al. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther. 1989;46:528-536.
58. Da Prada M, Zurcher G, Wuthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl. 1988;26:31-56.
59. Parkinson Study Group. Tyramine challenge to assess the safety of rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson's disease (the TEMPO Study) [abstract]. Neurology. 2001;56(suppl 3):A345.
60. Marcaida JA. Rasagiline does not promote tyramine pressor responses [abstract]. Mov Disord. 2005;20(suppl 10):S133.
61. Jacob JE, Wagner ML, Sage JI. Safety of selegiline with cold medications. Ann Pharmacother. 2003;37:438-441.
62. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. Lancet. 1991;337:246.
63. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology. 1997;48:1070-1077.
64. Ebadi M, Sharma S, Shavali S, El Refaey H. Neuroprotective actions of selegiline. J Neurosci Res. 2002;67:285-289.
65. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003;60:1234-1240.
66. Tatton WG, Chalmers-Redman RME. Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology. 1996; 47:S171-S183.
67. Tatton WG, Wadia JS, Ju WYH, Chalmers-Redman RM, Tatton NA. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl. 1996;48:45-49.
68. Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem. 1997;68:434-436.
69. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328:176-183.
70. Heikkila RE, Duvoisin RC, Finberg JP, Youdim MB. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol. 1985;116:313-317.
71. Kupsch A, Sautter J, Gotz ME, et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP1012) with selegiline. J Neural Transm. 2001;108:985-1009.
72. Youdim MBH, Wadia JS, Tatton WG. Neuroprotective properties of the antiparkinson drug rasagiline and its optical S-isomer [abstract]. Neurosci Lett. 1999;55:S45.
73. Maruyama W, Yamamoto T, Kitani K, Carrillo MC, Youdim M, Naoi M. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev. 2000;116:181-191.
74. Maruyama W, Takahashi T, Youdim MBH, Naoi M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm. 2002;109:467-481.
75. Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002;326:105-108.
76. Abu-Raya S, Blaugrund E, Trembovler V, et al. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. J Neurosci Res. 1999;58:456-463.
77. Goggi J, Theofilopoulos S, Riaz SS, Jauniaux E, Stern GM, Bradford HF. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurons in culture. Neuroreport. 2000;11:3937-3941.
78. Finberg JP, Takeshima T, Johnston JM, Commissiong JW. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport. 1998;9:703-707.
79. Bonneh-Barkay D, Ziv N, Finberg JP. Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells. Neuropharmacology. 2005;48:406-416.
80. Maruyama W, Akao Y, Youdim MBH, Naoi M. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm Suppl. 2000;60:171-186.
81. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. Exp Neurol. 2004;187:455-459.
82. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002;24:675-682.
83. Naoi M, Maruyama W, Youdim MB, Yu P, Boulton AA. Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase. Inflammopharmacology. 2003;11:175-181.
84. Yoles E, Schwartz M. N-propargyl-1(R)-aminoindan (TVP-1012), a putative neuroprotective agent, enhances in vitro neuronal survival after glutamate toxicity [abstract]. Proc Am Soc Neurosci. 1995; 21:562.
85. Pellegrini-Giampietro DE, Cozzi A, Peruginelli F, et al. 1-Aminoindan-1,5-dicarboxylic acid and (S)-(+)-2-(3′-carboxybicyclo[1.1.1] pentyl)-glycine, two mGlu1 receptor-preferring antagonists, reduce neuronal death in in vitro and in vivo models of cerebral ischaemia. Eur J Neurosci. 1999;11:3637-3647.
86. Carrillo MC, Minami C, Kitani K, et al. Enhancing effect of rasagiline on superoxide dismutase (SOD) and catalase (CAT) activities in the dopaminergic system in the rat. Life Sci. 2000;67:577-585.
87. Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)- aminoindan. J Neurochem. 2002;82:913-923.
88. Youdim MB, Amit T, Falach-Yogev M, Am OB, Maruyama W, Naoi M. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activation in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol. 2003;66:1635-1641.
89. Maruyama W, Akao Y, Youdim MBH, Boulton AA, Davis BA, Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of gluyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin N-methyl(R)salsolinol. J Neurochem. 2001;78:727-735.
90. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MB. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 2004;18:1471-1473.
91. Yogev-Falach M, Amit T, Bar-Am O, Youdim MB. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J. 2003;17:2325-2327.
92. Speiser Z, Mayk A, Eliash S, Cohen S. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm. 1999;106:593-606.
93. Speiser Z, Katzir O, Rehavi M, Zabarski T, Cohon S. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol Biochem Behav. 1998;60:387-393.
94. Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol. 1999;366:127-135.
95. Eliash S, Speiser Z, Cohen S. Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J Neural Transm. 2001;108:909-923.
96. Eliash S, Shteter N, Eilam R. Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. J Neural Transm. In press.
97. Maruyama W, Nitta A, Shamoto-Nagai M, et al. N-propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int. 2004;44:393-400.
98. Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MB. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem. 2004;89:1119-1125.
99. Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol. 1996;40:99-107.
100. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59:1541-1550.
101. Youdim MB, Fridkin M, Zheng H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev. 2005;126:317-326.